Pub Date : 2017-02-27DOI: 10.4172/2324-9110.1000172
M. Malone, Erika Mejia Hidalgo, Guofu Hu
Background: For quite a while, there has been controversy over whether or not angiogenin is associated with amyotrophic lateral sclerosis (ALS) risk. A lot of meta-analysis has been done in the last few years to support the fact that angiogenin has no relationship in improving the outcome and muscle strength in ALS. In the other hand, for about 3 decades angiogenin has been thought to play an important role in cell survival, growth, and proliferation. Evidence suggests that the expression and activity of ANG increases the odds of developing a variety of human cancers. We present the results of an observational study done in wild type (WT) and angiogenin knock out (ANG -/- KO) mice in order to determine phenotype and different features as explained below. Methods: We used 2 population of mice, 5 WT and 5 ANG -/- KO were involved in the study. They all were old, each 12 weeks old. These 2 populations were studied for a total of 8 weeks. We invested about 4 hours per day, 5 out 7 days per week. We had the mice running at different speeds on a treadmill in cycles of 300 seconds each, repeating these between 7-10 cycles per population. We used different speeds, being anywhere between 1 MPH to 7 MPH at the highest. We tested our theory that mice ANG -/- KO will have better strength and resistance by observing whether the mice looked stronger compared to the other population. Also by observation, we looked for physical abnormalities as well as evident malignancies in the ANG -/- KO vs. WT mice. Results: After conducting this study for 8 weeks, we found that ANG -/- KO mice did not have any statistical significant (p=0.36) muscle strength or resistance improvement compared to the WT mice. Also, at the end of our study we could conclude that ANG -/- KO did have less alopecia, skin cancer (basal cell carcinomas; squamous cell carcinomas), benign lesions of the skin, and malignant development of lymph nodes compared to WT mice. All 5 mice in the WT population did have skin lesions consistent with skin cancer and lymphadenopathy consistent with malignant lymph nodes of either lymphomas or metastatic disease. Discussion: At the end of the study, we could conclude that there was no statistical significance while evaluating both WT and KO mice as they had equal muscle strength and resistance. Conversely, we did see an increase in the number of benign and malignant proliferations in WT mice vs. KO mice.
{"title":"Lack of Association between Angiogenin (AGN) KO Mice with Improvement in Muscle Strength, Resistance,but Decreased in Chances of Tumorigenesis: Observational Study","authors":"M. Malone, Erika Mejia Hidalgo, Guofu Hu","doi":"10.4172/2324-9110.1000172","DOIUrl":"https://doi.org/10.4172/2324-9110.1000172","url":null,"abstract":"Background: For quite a while, there has been controversy over whether or not angiogenin is associated with amyotrophic lateral sclerosis (ALS) risk. A lot of meta-analysis has been done in the last few years to support the fact that angiogenin has no relationship in improving the outcome and muscle strength in ALS. In the other hand, for about 3 decades angiogenin has been thought to play an important role in cell survival, growth, and proliferation. Evidence suggests that the expression and activity of ANG increases the odds of developing a variety of human cancers. We present the results of an observational study done in wild type (WT) and angiogenin knock out (ANG -/- KO) mice in order to determine phenotype and different features as explained below. \u0000Methods: We used 2 population of mice, 5 WT and 5 ANG -/- KO were involved in the study. They all were old, each 12 weeks old. These 2 populations were studied for a total of 8 weeks. We invested about 4 hours per day, 5 out 7 days per week. We had the mice running at different speeds on a treadmill in cycles of 300 seconds each, repeating these between 7-10 cycles per population. We used different speeds, being anywhere between 1 MPH to 7 MPH at the highest. We tested our theory that mice ANG -/- KO will have better strength and resistance by observing whether the mice looked stronger compared to the other population. Also by observation, we looked for physical abnormalities as well as evident malignancies in the ANG -/- KO vs. WT mice. \u0000Results: After conducting this study for 8 weeks, we found that ANG -/- KO mice did not have any statistical significant (p=0.36) muscle strength or resistance improvement compared to the WT mice. Also, at the end of our study we could conclude that ANG -/- KO did have less alopecia, skin cancer (basal cell carcinomas; squamous cell carcinomas), benign lesions of the skin, and malignant development of lymph nodes compared to WT mice. All 5 mice in the WT population did have skin lesions consistent with skin cancer and lymphadenopathy consistent with malignant lymph nodes of either lymphomas or metastatic disease. \u0000Discussion: At the end of the study, we could conclude that there was no statistical significance while evaluating both WT and KO mice as they had equal muscle strength and resistance. Conversely, we did see an increase in the number of benign and malignant proliferations in WT mice vs. KO mice.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43767379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-27DOI: 10.4172/2324-9110.1000179
Sema Yilmaz Rakici, C. Bilir, G. Tufan, Z. Yazici
Parathyroid cancers (PTC) are very rare and have a poor prognosis. A 48 year old case with locally invasive PTC that was positive for close surgical removal margin was treated with chemo radiotherapy after surgery. Even though this required bimodal chemo and radio adjuvant therapy, the patient was treated by chemo radiotherapy with some modifications, including oral administration of capestabine. These treatments were well tolerated with minimal side effects, which have proven to be very effective in freeing the patient from the invasive tumor for the following twenty six months of monitoring. This treatment method could be adopted in place of the widely preferred surgical therapy. We believe that this case report will guide future studies concerning with similar cases.
{"title":"Chemoradiotherapy In Locally Invasive Parathyroid Cancer","authors":"Sema Yilmaz Rakici, C. Bilir, G. Tufan, Z. Yazici","doi":"10.4172/2324-9110.1000179","DOIUrl":"https://doi.org/10.4172/2324-9110.1000179","url":null,"abstract":"Parathyroid cancers (PTC) are very rare and have a poor prognosis. A 48 year old case with locally invasive PTC that was positive for close surgical removal margin was treated with chemo radiotherapy after surgery. Even though this required bimodal chemo and radio adjuvant therapy, the patient was treated by chemo radiotherapy with some modifications, including oral administration of capestabine. These treatments were well tolerated with minimal side effects, which have proven to be very effective in freeing the patient from the invasive tumor for the following twenty six months of monitoring. This treatment method could be adopted in place of the widely preferred surgical therapy. We believe that this case report will guide future studies concerning with similar cases.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42802879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-24DOI: 10.4172/2324-9110.1000175
H. Hassoun, Sattar Al-Essawi, T. Tiraihi, A. A. Wahab, A. Rasheed, Imad Al-Sabri, Zuhair Allebban
Primary diffuse leptomeningeal Gliomatosis (PDLG) is a rare neoplastic condition characterized by primary infiltration of leptomeninges by malignant glial cells which is extremely rare to be as a result of medulloblastoma. To the best of our knowledge, there are only 5 reported localized forms of PDLG cases due to medulloblastoma affecting mainly posterior fossa and/or part of cerebrum. In this article, we are reporting for the first time a case of PDLG with extensive diffuse involvement of leptomeninges due to medulloblastoma extending from the cerebrum to sacral area in 4-year old child presented with acute headache, abducent nerve palsy and papilledema with dramatic response to chemotherapy.
{"title":"Can Medulloblastoma be Presented with Primary Diffuse Leptomeningeal Gliomatosis? Case Report and Literature Review","authors":"H. Hassoun, Sattar Al-Essawi, T. Tiraihi, A. A. Wahab, A. Rasheed, Imad Al-Sabri, Zuhair Allebban","doi":"10.4172/2324-9110.1000175","DOIUrl":"https://doi.org/10.4172/2324-9110.1000175","url":null,"abstract":"Primary diffuse leptomeningeal Gliomatosis (PDLG) is a rare neoplastic condition characterized by primary infiltration of leptomeninges by malignant glial cells which is extremely rare to be as a result of medulloblastoma. To the best of our knowledge, there are only 5 reported localized forms of PDLG cases due to medulloblastoma affecting mainly posterior fossa and/or part of cerebrum. In this article, we are reporting for the first time a case of PDLG with extensive diffuse involvement of leptomeninges due to medulloblastoma extending from the cerebrum to sacral area in 4-year old child presented with acute headache, abducent nerve palsy and papilledema with dramatic response to chemotherapy.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43224018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-21DOI: 10.4172/2324-9110.1000176
C. Rodrigues, D. Romeira, M. Pinto, Ana Massena, H. Mir, Ana Martins Mourão
Tumour infiltrating lymphocytes have been associated to a better prognosis in colorectal cancers. Microsatellite unstable tumours present a greater infiltration by these immune cells when comparing to microsatellite stable tumours. It has been suggested that lymphocytic infiltration may be an indicator of a host immune response against tumour cells and therefore, contribute to a better prognosis. High microsatellite instability (MSI-H) tumours have been shown to bare a better prognosis and some authors believe that TILs infiltration take a part in this. Nonetheless, the significance of tumour infiltrating lymphocytes (TILs), their distribution and prognostic value are still unclear. The aim of this review is to summarize the current evidence on tumour infiltrating lymphocytes characteristics, distribution, activity and relation to prognosis in microsatellite unstable colorectal tumours.
{"title":"Immunosurveillance in Colorectal Carcinomas with Microsatellite Instability","authors":"C. Rodrigues, D. Romeira, M. Pinto, Ana Massena, H. Mir, Ana Martins Mourão","doi":"10.4172/2324-9110.1000176","DOIUrl":"https://doi.org/10.4172/2324-9110.1000176","url":null,"abstract":"Tumour infiltrating lymphocytes have been associated to a better prognosis in colorectal cancers. Microsatellite unstable tumours present a greater infiltration by these immune cells when comparing to microsatellite stable tumours. It has been suggested that lymphocytic infiltration may be an indicator of a host immune response against tumour cells and therefore, contribute to a better prognosis. High microsatellite instability (MSI-H) tumours have been shown to bare a better prognosis and some authors believe that TILs infiltration take a part in this. Nonetheless, the significance of tumour infiltrating lymphocytes (TILs), their distribution and prognostic value are still unclear. The aim of this review is to summarize the current evidence on tumour infiltrating lymphocytes characteristics, distribution, activity and relation to prognosis in microsatellite unstable colorectal tumours.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41483205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-20DOI: 10.4172/2324-9110.1000173
P. Dombi, H. Andrikovics, Á. Illés, J. Demeter, L. Homor, Z. Simon, M. Udvardy, Á. Kellner, M. Egyed
Objective: The Hungarian National Registry for Philadelphia chromosome negative myeloproliferative neoplasms was used to assess the clinical characteristics of Hungarian patients with polycythemia vera. Methods: Data from 351 JAK2 V617F-positive patients diagnosed with PV were collected online from 15 haematology centres reporting clinical characteristics, therapeutic interventions, venous and arterial thromboembolic events, and myelofibrotic or leukaemic transformations. Vascular events (thromboembolic and haemorrhagic) were evaluated before and after diagnosis based upon the Landolfi risk assessment scale. Results: TE were reported on 116 occasions (106 patients) before diagnosis and 152 occasions (102 cases) during follow-up. Compared to before diagnosis, after diagnosis frequency of major arterial events decreased from 11.7% to 2.6% (p<0.0001), and minor venous events increased from 2.0% to 14.2% (p<0.0001); there was no significant change in number of major venous events (from 6.3% to 8.8%; p=0.25) or minor arterial events (from 13.1% to 17.7%; p=0.12). Bleeding events were recorded in 6.4% of patients. Despite treatment, 42.2% of patients with prior thromboembolic events had recurrent thromboembolic complications. After diagnosis age and prior history of thromboembolic events were independent risk factors for arterial events, and white blood cells and diabetes for venous events. Hydroxyurea use in the low+moderate risk Landolfi group slightly, but not significantly, increased thromboembolic event risk (p=0.74). Conclusions: This registry enables characterisation of patients with polycythemia vera. Data suggest the need for accuracy of diagnostic criteria and compliance with risk-adapted therapeutic guidelines.
{"title":"Thromboembolic Events in Polycythaemia Vera Patients:An Audit of the Hungarian Philadelphia Negative Chronic Myeloproliferative Neoplasia Register","authors":"P. Dombi, H. Andrikovics, Á. Illés, J. Demeter, L. Homor, Z. Simon, M. Udvardy, Á. Kellner, M. Egyed","doi":"10.4172/2324-9110.1000173","DOIUrl":"https://doi.org/10.4172/2324-9110.1000173","url":null,"abstract":"Objective: The Hungarian National Registry for Philadelphia chromosome negative myeloproliferative neoplasms was used to assess the clinical characteristics of Hungarian patients with polycythemia vera. \u0000Methods: Data from 351 JAK2 V617F-positive patients diagnosed with PV were collected online from 15 haematology centres reporting clinical characteristics, therapeutic interventions, venous and arterial thromboembolic events, and myelofibrotic or leukaemic transformations. Vascular events (thromboembolic and haemorrhagic) were evaluated before and after diagnosis based upon the Landolfi risk assessment scale. \u0000Results: TE were reported on 116 occasions (106 patients) before diagnosis and 152 occasions (102 cases) during follow-up. Compared to before diagnosis, after diagnosis frequency of major arterial events decreased from 11.7% to 2.6% (p<0.0001), and minor venous events increased from 2.0% to 14.2% (p<0.0001); there was no significant change in number of major venous events (from 6.3% to 8.8%; p=0.25) or minor arterial events (from 13.1% to 17.7%; p=0.12). Bleeding events were recorded in 6.4% of patients. Despite treatment, 42.2% of patients with prior thromboembolic events had recurrent thromboembolic complications. After diagnosis age and prior history of thromboembolic events were independent risk factors for arterial events, and white blood cells and diabetes for venous events. Hydroxyurea use in the low+moderate risk Landolfi group slightly, but not significantly, increased thromboembolic event risk (p=0.74). \u0000Conclusions: This registry enables characterisation of patients with polycythemia vera. Data suggest the need for accuracy of diagnostic criteria and compliance with risk-adapted therapeutic guidelines.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46593942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-20DOI: 10.4172/2324-9110.1000174
K. Suyama, Y. Miura, T. Takano, H. Iwase
Significant progress has been made in systemic chemotherapies for advanced cancer patients. Historically, the main anticancer drugs were cytotoxic agents, but recently, other agents such as molecularly-targeted therapies and immune checkpoint inhibitors have been introduced into clinical practice, and these agents have begun to achieve mainstream usage. The rapid development of novel anticancer drugs has forced clinicians to consider the effects of these chemotherapy agents in high-risk patients with liver or renal dysfunction, those undergoing dialysis and the elderly. Currently, there are no clear guidelines describing the best practices for anticancer drug administration in patients with renal dysfunction. However, the theory that renal dysfunction affects the ability of patients to cope with anticancer therapies is understandable compared with liver dysfunction or other risk factors. That is why there has always been an indication for dose adjustments for patients with renal dysfunction. In this review, recommended dose adjustments in cases of renal dysfunction are discussed based on the latest information on anticancer drugs.
{"title":"Chemotherapy for Patients with Renal Dysfunction","authors":"K. Suyama, Y. Miura, T. Takano, H. Iwase","doi":"10.4172/2324-9110.1000174","DOIUrl":"https://doi.org/10.4172/2324-9110.1000174","url":null,"abstract":"Significant progress has been made in systemic chemotherapies for advanced cancer patients. Historically, the main anticancer drugs were cytotoxic agents, but recently, other agents such as molecularly-targeted therapies and immune checkpoint inhibitors have been introduced into clinical practice, and these agents have begun to achieve mainstream usage. The rapid development of novel anticancer drugs has forced clinicians to consider the effects of these chemotherapy agents in high-risk patients with liver or renal dysfunction, those undergoing dialysis and the elderly. Currently, there are no clear guidelines describing the best practices for anticancer drug administration in patients with renal dysfunction. However, the theory that renal dysfunction affects the ability of patients to cope with anticancer therapies is understandable compared with liver dysfunction or other risk factors. That is why there has always been an indication for dose adjustments for patients with renal dysfunction. In this review, recommended dose adjustments in cases of renal dysfunction are discussed based on the latest information on anticancer drugs.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45312556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2324-9110-C1-005
N. Kostovic
Today's standard technological advances are only capable of performing laser medical surgeries at the strength of Mili Amperes which is: 1A= 1,000 Mili Amperes. Using the power of only 6-10 volts of electricity this equates to electric shock or most probably lethal shock. So it is too dangerous to heal unhealthy organs. The K-BTE device also has the ability of maintaining the bone and muscle tissue of astronauts in space. Currently, Astronauts’ orbits are limited to six (6) months since they suffer from deterioration of bone tissue and show significant muscle atrophy. With that said, there are no circumstances – such as gravitation, vacuum, or any type of energetic field irradiation – that would have any detrimental influence on K-BTE's own energetic field. This would allow for the maintenance of Astronauts’ bone and muscle tissue while in space thus preventing any decline or deterioration. This enriched-electrons-radiation-emitting-process is absolutely nonradioactive, non-toxic and is, in no way, “shock therapy”. Nick Kostovic Bio Technological Health Center, Inc., Torrance, CA 90503, USA. Submission: 26 September 2016 Accepted: 1 October 2016 Published: 25 October 2016 www.ijppr.humanjournals.com Citation: Nick Kostovic et al. Ijppr.Human, 2016; Vol. 7 (3): 1-4. 2 Today's standard technological advances are only capable of performing laser medical surgeries at the strength of Mili Amperes which is: 1A= 1,000 Mili Amperes. Using the power of only 6-10 volts of electricity this equates to electric shock or most probably lethal shock. So it is too dangerous to heal unhealthy organs. The Kostovic Bio-Technology Energetic Device has the ability to extract bioelectron's photons from H2O electric fluid. Creating 1A= 1,000,000 Micro Amperes and 1A = 1,000,000,000 Nano Amperes. Using the power of 120 Voltages or 240 Voltages or more, but creating Microamperes or even Nano Amperes we do not create any electric shock, nor is it at all lethal. Instead, Nick Kostovic discovered the technology to produce photons of electrons at this Micro and Nanoamperes level that is gentle yet precise and efficient in burning off the dead cells and energizing the hibernating healthy cells in the central nervous vascular system and the organs that he is working on. Capable of performing all types of laser medical surgeries on the brain, heart, breast cancer or other cancers in any other physical organ with no harm to the healthy cells and no side effects. He has been performing treatments for last 15 years with more than 40,000 hours using the gentle strength of Micro Amperes and Nano Amperes. -Micro Amperes maximum strength output between the first energetic field and the second energetic field on the floor of K-BTE( see diagram)are using 2 D/C Micro Amperes to 15 D/C Micro Amperes, with an average of 8.5 Direct Current, D/C Micro Amperes. -This measured current is confirmed for the body's resistance from 1,000 /wet/ Ohms to 100,000 /dry/ Ohms or more, it doesn't even mat
{"title":"New advanced technology in medicine by bio electrons photons special circuit","authors":"N. Kostovic","doi":"10.4172/2324-9110-C1-005","DOIUrl":"https://doi.org/10.4172/2324-9110-C1-005","url":null,"abstract":"Today's standard technological advances are only capable of performing laser medical surgeries at the strength of Mili Amperes which is: 1A= 1,000 Mili Amperes. Using the power of only 6-10 volts of electricity this equates to electric shock or most probably lethal shock. So it is too dangerous to heal unhealthy organs. The K-BTE device also has the ability of maintaining the bone and muscle tissue of astronauts in space. Currently, Astronauts’ orbits are limited to six (6) months since they suffer from deterioration of bone tissue and show significant muscle atrophy. With that said, there are no circumstances – such as gravitation, vacuum, or any type of energetic field irradiation – that would have any detrimental influence on K-BTE's own energetic field. This would allow for the maintenance of Astronauts’ bone and muscle tissue while in space thus preventing any decline or deterioration. This enriched-electrons-radiation-emitting-process is absolutely nonradioactive, non-toxic and is, in no way, “shock therapy”. Nick Kostovic Bio Technological Health Center, Inc., Torrance, CA 90503, USA. Submission: 26 September 2016 Accepted: 1 October 2016 Published: 25 October 2016 www.ijppr.humanjournals.com Citation: Nick Kostovic et al. Ijppr.Human, 2016; Vol. 7 (3): 1-4. 2 Today's standard technological advances are only capable of performing laser medical surgeries at the strength of Mili Amperes which is: 1A= 1,000 Mili Amperes. Using the power of only 6-10 volts of electricity this equates to electric shock or most probably lethal shock. So it is too dangerous to heal unhealthy organs. The Kostovic Bio-Technology Energetic Device has the ability to extract bioelectron's photons from H2O electric fluid. Creating 1A= 1,000,000 Micro Amperes and 1A = 1,000,000,000 Nano Amperes. Using the power of 120 Voltages or 240 Voltages or more, but creating Microamperes or even Nano Amperes we do not create any electric shock, nor is it at all lethal. Instead, Nick Kostovic discovered the technology to produce photons of electrons at this Micro and Nanoamperes level that is gentle yet precise and efficient in burning off the dead cells and energizing the hibernating healthy cells in the central nervous vascular system and the organs that he is working on. Capable of performing all types of laser medical surgeries on the brain, heart, breast cancer or other cancers in any other physical organ with no harm to the healthy cells and no side effects. He has been performing treatments for last 15 years with more than 40,000 hours using the gentle strength of Micro Amperes and Nano Amperes. -Micro Amperes maximum strength output between the first energetic field and the second energetic field on the floor of K-BTE( see diagram)are using 2 D/C Micro Amperes to 15 D/C Micro Amperes, with an average of 8.5 Direct Current, D/C Micro Amperes. -This measured current is confirmed for the body's resistance from 1,000 /wet/ Ohms to 100,000 /dry/ Ohms or more, it doesn't even mat","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70249682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01DOI: 10.4172/2324-9110-C1-006
H. Parsian
{"title":"Comparison of serum antioxidant enzymes status in early and advance stage of breast cancer after five weeks radiotherapy","authors":"H. Parsian","doi":"10.4172/2324-9110-C1-006","DOIUrl":"https://doi.org/10.4172/2324-9110-C1-006","url":null,"abstract":"","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70250121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-12DOI: 10.4172/2324-9110.1000169
N. Clemente, Lara Aless, Rini, G. Giorda, F. Sopracordevole
Endometrial cancer is the most common gynecological malignancy, and it usually presents with abnormal uterine bleeding as initial symptom. Cases of advanced endometrial cancer with uncommon symptoms at presentation are reported in the literature but, to our knowledge, no case an of enterouterine fistula as the initial presentation of the disease has been previously described. We report the case of a 54-year-old woman, with a 2-month history of permanent vaginal discharge of partly non-digested stool masses due to an enterouterine fistula that was the initial presentation of an advanced endometrial cancer. Interestingly, in this case, not all the preoperative exams (CT, colonoscopy and hysteroscopy) identified the fistulous openings, and the enterouterine fistula was confirmed only at the time of surgery.
{"title":"Enterouterine Fistula as Initial Presentation of Advanced Endometrial Cancer: Description of a Rare Case and Review of the Literature","authors":"N. Clemente, Lara Aless, Rini, G. Giorda, F. Sopracordevole","doi":"10.4172/2324-9110.1000169","DOIUrl":"https://doi.org/10.4172/2324-9110.1000169","url":null,"abstract":"Endometrial cancer is the most common gynecological malignancy, and it usually presents with abnormal uterine bleeding as initial symptom. Cases of advanced endometrial cancer with uncommon symptoms at presentation are reported in the literature but, to our knowledge, no case an of enterouterine fistula as the initial presentation of the disease has been previously described. We report the case of a 54-year-old woman, with a 2-month history of permanent vaginal discharge of partly non-digested stool masses due to an enterouterine fistula that was the initial presentation of an advanced endometrial cancer. Interestingly, in this case, not all the preoperative exams (CT, colonoscopy and hysteroscopy) identified the fistulous openings, and the enterouterine fistula was confirmed only at the time of surgery.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70249896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-12DOI: 10.4172/2324-9110.1000171
E. Atağ, S. Kazaz, H. Semiz, I. T. Unek, S. Sarıoğlu, T. Yavuzşen
A 63-year-old man was admitted to our hospital with 2 months history of dysphagia. Endoscopic examination revealed an ulserovegetan tumor starting from distal esophagus and extending to the cardia. Pathological examination of the biopsy revealed an epithelial malignant tumor without further classification. The patient underwent a surgery following neo-adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucoverin (FOLFOX) regimen. Postoperative pathological analyses showed high grade EBV-associated lymphoepithelioma-like carcinoma of the gastroesophagial junction and stomach. After surgery, we planned to administered 6 cycles of FOLFOX regimen as an adjuvant treatment. Lymphoepithelioma-like gastric carcinoma is a rare type of gastric carcinoma and has distinct clinic-pathologic characteristics, including male predominance, preferential location in the gastric cardia, lymphocytic infiltration, a lower frequency of lymph node metastases and more favorable prognosis. Surgical resection is the most effective treatment modality. Chemotherapy may be considered for patients who have high risk factors.
{"title":"Epstein-Barr Virus Associated Lymphoepithelioma-Like Carcinoma of the Esophagogastric Junction and Stomach: A Case Report and Review of the Literature","authors":"E. Atağ, S. Kazaz, H. Semiz, I. T. Unek, S. Sarıoğlu, T. Yavuzşen","doi":"10.4172/2324-9110.1000171","DOIUrl":"https://doi.org/10.4172/2324-9110.1000171","url":null,"abstract":"A 63-year-old man was admitted to our hospital with 2 months history of dysphagia. Endoscopic examination revealed an ulserovegetan tumor starting from distal esophagus and extending to the cardia. Pathological examination of the biopsy revealed an epithelial malignant tumor without further classification. The patient underwent a surgery following neo-adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucoverin (FOLFOX) regimen. Postoperative pathological analyses showed high grade EBV-associated lymphoepithelioma-like carcinoma of the gastroesophagial junction and stomach. After surgery, we planned to administered 6 cycles of FOLFOX regimen as an adjuvant treatment. Lymphoepithelioma-like gastric carcinoma is a rare type of gastric carcinoma and has distinct clinic-pathologic characteristics, including male predominance, preferential location in the gastric cardia, lymphocytic infiltration, a lower frequency of lymph node metastases and more favorable prognosis. Surgical resection is the most effective treatment modality. Chemotherapy may be considered for patients who have high risk factors.","PeriodicalId":73658,"journal":{"name":"Journal of clinical & experimental oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70249960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：